Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Dublin, Aug. 16, 2017 -- The "R&D and Business Tracker for Antibody-Drug Conjugates" newsletter has been added to Research and Markets' offering.
This information service about Antibody-Drug Conjugates (ADCs) delivers 12 monthly update reports in pdf format by e-mail straight to your desk and provides online access to the author's R&D database for the subject field of the service during the one-year subscription period. Credentials to access the online database will be sent by e-mail within 24 hours after purchase.
This product consists of:
- 12 monthly update reports in pdf format delivered by e-mail; and
- Online access to ADC R&D database during the 1-year subscription period.
The monthly update report about Antibody-Drug Conjugates contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
Business Tracker for:
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
Clinical Trial Tracker
Scientific Publication Tracker
Featured Cell Therapy Profile
Featured Company Profile
Featured Target or Technology Pipeline
For more information about this newsletter visit https://www.researchandmarkets.com/research/xvprdr/randd_and
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs
